The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

We would like to draw attention to the latest advances in the field of peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) of gastroenteropancreatic origin. The term NET refers to well-differentiated tumors that can be grade 1 (Ki-67 index, <3), 2 (Ki-67, 3–20), or 3 (Ki-